Scouting report · CAI

David Dean HalbertFounder

Founded Caris in 2008; Chairman & CEO since; controls 43.9% of the stock

Born / age
(70)
Role
Founder, Chairman & CEO
In the role
19 yr
Education
BBA Abilene Christian University
Front Office rank
not ranked yet
CAI
Caris Life Sciences, Inc.Diagnostics
Title
Founder, Chairman & CEOsrc
In role
since 2008 (19 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 24 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design50revenue, ebitda, fcf, strategic, time only · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
David Dean Halbert
Age
70src
Education
BBA Business Administration, Abilene Christian University (1978)src
Founder
Yes

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
125,009,756 CAI, 2026-03-31src
Share of company
43.9%
Traded, 12 months
bought $0, sold $0src
Last pay
$20.4m 2025src

What to weigh

Red flag 1

  • 25,000,000 shares held by Halbert Family Capital, LLC are pledged as collateral for his personal debt, about a fifth of his 125.0m-share stakesrc

Watch 5

  • The company is controlled by its founder. He holds 43.9% and all directors and officers together hold 50.0%. He is both Chairman and CEO, with a lead independent directorsrc
  • Related-party aircraft: Caris uses a plane owned by his family office and leases its own plane to Caris Air, an operator affiliated with him. He and his family also use the company's plane personally under a time-sharing agreement signed in October 2025. Net payments to Caris Air were $2.1m in 2025src
  • 2025 pay totalled $20.35m, up from $2.25m in 2024. It included $1.5m in special cash bonuses for completing the crossover round and the IPO, 360,750 RSUs that vested outright on the IPO, and $925,773 of personal securitysrc
  • As an emerging growth company, Caris holds no say-on-pay vote and discloses no CD&A or CEO pay ratio. At the June 2026 meeting 17.4% of votes cast were withheld from his re-electionsrc
  • The 10-Q he signed reports disclosure controls not effective at 2026-06-30, because a material weakness (too few qualified accounting staff) found in the FY2024 audit is still unremediatedsrc

In their favour 2

  • No open-market sales since the June 2025 IPO. His only reported dispositions are shares withheld for tax on RSU vestingsrc
  • From 2026 his annual bonus is based entirely on company performance metrics, where the 2025 bonus was set at the committee's discretionsrc

Pay

Salary and otherBonus, stock, options, incentive

  • $2.2m2024
  • $20.4m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2024$750k$1.5m$0$0$0$0$2.2msrc
2025$765k$3.3m$15.4m$0$0$926k$20.4msrc
Bonus pays on
Discretionary cash bonus, target 200% of salary, paid at 115% after the committee reviewed revenue, clinical volume, adjusted EBITDA, FCF and pipeline; plus two $750k deal bonuses (crossover, IPO). From 2026 a formula plan, 100% company metrics for him
Long-term award pays on
Time-vested RSUs only: 413,839 IPO RSUs vesting 25% a year each May 15; 360,750 RSUs vested on the IPO itself; no options granted in 2025src
  • Pay at risk not on file
  • Pays on returns revenue, ebitda, fcf, strategic, time only
  • Shareholder vote not on file
  • Pay vs profit company lost money

Career

  1. 2008 – now
    Caris Life Sciencessrc
    Founder, Chairman & CEO
    Led the April 2025 private crossover financing and the June 2025 IPO at $21 a share
  2. 2005 – 2011
    Caris Diagnosticssrc
    Chairman & CEO
    Texas gastrointestinal-pathology company and Caris Life Sciences' former parent; sold to Miraca Life Sciences in 2011
  3. 1987 – 2004
    AdvancePCSsrc
    Founder, Chairman & CEO
    Prescription benefit plan administrator he founded in 1987; merged with CVS Caremark in 2004. The search summary puts the sale at $7.5bn and revenue above $15bn (WS-bio), not checked against a filing

Not located: 2004 to 2005, between the AdvancePCS merger and Caris Diagnostics, is not described in any source read

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family His brother Jon S. Halbert, who co-founded AdvancePCS with him, has sat on the Caris board since 2014. The proxy names no other family relationship among directors and officerssrc
  • Family His son was an employee from June 2011 and later Senior Vice President, Human Resources. He was not an executive officer. He left voluntarily under a transition agreement signed in November 2025, resigning on 2026-05-16, and received $435,930 in cash for 2025src
  • Family He and his spouse personally guarantee the lease on the Irving, Texas head office, which runs to April 2028src
  • Family Immediate family members bought 22,000 shares at the $21 IPO price through the directed share programsrc
  • Giving He and his family created the Caris Foundation in 2002 and are its only funders. It is a private foundation that helps impoverished people meet basic needssrc
  • Giving According to the search summary, he and his wife gave $15m toward the Halbert-Walling Research Center at Abilene Christian University, which opened in 2017src
  • Other Three board members go back with him. Laura Johansen, an independent director on the compensation committee, ran his family office (Halbert & Associates) from 2004 to 2010 and was AdvancePCS general counsel. Danny Phillips, the audit chair, was AdvancePCS CFO. His brother Jon was AdvancePCS vice chairmansrc
  • Other He has no change-in-control plan participation (all other senior executives have one) and no disclosed employment agreement, only an inventions-assignment agreementsrc

Sources9